Navigation Links
Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Date:1/8/2008

tment period. The primary efficacy endpoint of the trial will be the increase from baseline in spontaneous bowel movements per week (SBMs per week). Additional endpoints include monitoring of other symptoms of OBD, which will include the Patient Assessment of Constipation Symptoms (PAC-SYM) outcomes tool, and other quality of life measures. Maintenance of opioid analgesic effect will be assessed by measuring changes from baseline in mean daily opioid requirements and daily pain scores. Safety and tolerability will be assessed and pharmacokinetics of the drug will be evaluated. The trial will be conducted in approximately 50 centers in North America and Europe.

About NKTR-118

NKTR-118 is an oral drug that combines Nektar's advanced small molecule PEGylation technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. In preclinical studies, Nektar's PEGylation technology has been shown to reduce penetration of drugs across the blood-brain barrier, an important potential advance for NKTR-118 and possibly many other small molecule therapies.

The peripheral opioid antagonist NKTR-118 targets opioid receptors within the enteric nervous system, which mediate OBD, a symptom complex resulting from opioid use that encompasses constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome, and is generally its most prominent component. Currently, there are no specific drugs approved or specifically indicated to treat OBD or OIC. NKTR-118 has been studied in two Phase 1 trials evaluating the safety, tolerability and pharmacokinetics of single and repeated dose administration of the drug.

In a proof-of-principle Phase 1 trial, single oral doses of NKTR-118 antagonized morphine-induced delay in gastrointestinal transit time demonstrating the potential of the drug to relieve constipation caused by opioid treatment. This effect was seen to increase in a dose-dependent fas
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
7. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
8. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
9. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
10. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
11. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 Hitachi Chemical Diagnostics, ... States launch of the ExoComplete™ 96-Well Plate ... easy system for exosome collection to mRNA purification.  The ... Vesicles ("ISEV") Annual Meeting, April 23 – 26, 2015, ... are intended for research use only of molecular biology ...
(Date:5/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/63gppw/asian_dermatology ) ... Market by Type, by End User - Forecast to 2019" ... Devices market is estimated to grow at a CAGR of ... holds a larger share in the Dermatology devices market around ... The Asian Dermatology Devices market holds a high potential for ...
(Date:5/1/2015)... --  Heska Corporation (NASDAQ: HSKA - ... advanced veterinary diagnostic and other specialty veterinary products , today ... at the 16th Annual B. Riley & Co. Investor Conference ... will be held May 12-14, 2015 at Lowes Hollywood Hotel, ... be available during the day on May 13 for one-on-one ...
Breaking Medicine Technology:New Products for Exosome Isolation to mRNA Purification 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 3Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2
... Pharmaceuticals Inc. (NASDAQ: VNDA ) announced ... Vanda,s sublicensor Novartis Pharma AG, has initiated a ... depot) formulation of Fanapt® (iloperidone).  This is a ... and pharmacokinetic profiles of two different long-acting formulations ...
... Noverca – the first and currently only Italian ,Full ... presence in the Health and Wellness Sector . ... has been developed and launched thanks to the long-term ... o verca) and Fatebenefratelli Hospital. Davide ...
Cached Medicine Technology:Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 2Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 3EXTENDED HEALTH: Noverca Enters the World of Healthcare 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 ... just released the first-ever congenital heart disease ... Catheterization Laboratory (PCCL) accreditation. Driven by the ... are a comprehensive review of interventional procedures ... heart disease. , “The ACE CHD Standards ...
(Date:5/4/2015)... Sara Soulati, CEO of Global ... in Los Angeles associated with the field of Enhanced ... The Sara Soulati Health For Life Program (SSHFLP). , ... lifestyle modification and disease prevention program. A provisional ... S. Patents and Trademarks Office and is now under ...
(Date:5/3/2015)... VEGAS and LOS ANGELES, American Telemedicine Association 2015 ... vitaphone e-health solutions, a full-service telemedicine ... launch of its new platform, VITA health services ... The VITA health services platform enables remote patient ... such as congestive heart failure (CHF), diabetes, COPD, ...
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch ... latest and coolest technology products available to consumers. Scott Steinberg, ... review and shared with viewers how to protect their private ... is on computers and even more so online. It helps ... all over the world. In terms of work, the internet ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 It is not too ... Brain Aneurysm Walk in Memory of Lissa Anne Been in ... organized this great family-friendly event to honor her loving memory. It ... inception. , Just having turned 37, Lissa suffered a ... away on August 24, 2012. This event is designed to serve ...
Breaking Medicine News(10 mins):Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2
... invented at The University of Texas M. D. Anderson Cancer ... III clinical trial for cancer, as announced today at the ... , Introgen Therapeutics, Inc., reported results of its phase III ... gene p53, for end-stage head and neck cancer. , "Cells ...
... select winning online health applications, REDMOND, ... award funding from $3 million to $4.5 ... academic and research health,organizations across the United ... Proposals represent a wide range of innovative ...
... 28 The Gladney Center,for Adoption, Fort Worth, ... Melson to the newly-created position of Executive Vice ... responsible for creating,managing and implementing funding programs that ... bright futures around the globe through,adoption programs and ...
... 28 VirtualHealth,Technologies, Inc. (OTC Bulletin Board: VHGI) ... of Operations effective immediately. Robert,previously served as COO ... past 4 years,and joined VHGI as part of ... Robert has over 21 years experience in the ...
... May 28 At today,s Altria,(Philip Morris USA) ... against public health and tobacco control,measures. America,s largest ... Act recently introduced in the U.S. House of,Representatives ... labeling, tracking and reporting by the tobacco industry., ...
... May 2008 - You went to a wedding yesterday. The ... was dancing all night. But people tell you that you ... weeks, and that you didnt go to a wedding yesterday ... this following neurological damage is known as confabulation. The reasons ...
Cached Medicine News:Health News:Gene therapy increases survival for end-stage head and neck cancer 2Health News:Gene therapy increases survival for end-stage head and neck cancer 3Health News:Gene therapy increases survival for end-stage head and neck cancer 4Health News:Microsoft HealthVault Be Well Fund Increased to $4.5 Million 2Health News:Microsoft HealthVault Be Well Fund Increased to $4.5 Million 3Health News:Microsoft HealthVault Be Well Fund Increased to $4.5 Million 4Health News:Microsoft HealthVault Be Well Fund Increased to $4.5 Million 5Health News:The Gladney Center for Adoption Names Mark L. Melson as Executive Vice President/Chief Development Officer 2Health News:VirtualHealth Technologies, Inc. Announces Management Appointment 2Health News:Shareholders Demand Philip Morris USA Stop Interfering in Health Policy 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: